Conference Proceedings

Patterns and management of progression on first-line ipilimumab combined with anti-PD-1 (IPI PD1) in metastatic melanoma (MM) patients.

Ines Pires Da Silva, Judith M Versluis, Tasnia Ahmed, Douglas Buckner Johnson, Jennifer Soon, Clara Allayous, Camille Lea Gerard, Joanna Mangana, Oliver Klein, Lisa Zimmer, Caroline Robert, Maria Grazia Vitale, Hui-Ling Yeoh, Olivier Michielin, Celeste Lebbe, Shahneen Kaur Sandhu, Christian U Blank, Matteo S Carlino, Alexander M Menzies, Georgina V Long

Journal of Clinical Oncology | American Society of Clinical Oncology (ASCO) | Published : 2021

Abstract

9533 Background: First line IPI+PD1 induces long-term response in 36% of MM patients (pts); however, the majority of pts will progress and may require further treatment, which is yet to be established. We studied the patterns of progressive disease (PD) on 1st line IPI+PD1, and the management and outcomes in MM pts. Methods: Demographics, disease characteristics, nature of PD, subsequent treatments and outcomes were examined in MM pts with PD on 1st line IPI+PD1. Multivariable analyses (MVA) identified factors associated with patterns of PD: innate resistance (IR) = PD as best response or stable disease (SD) < 6 mo; acquired resistance (AR) = PD after initial response or SD ≥ 6 mo. Results:..

View full abstract